RPP0B Antibody

Potential Nomenclature Errors

The term "RPP0B" may represent a typographical error, outdated nomenclature, or mischaracterization of a known target. Below are related terms that appear in the literature:

Antibody Validation in RPPA Studies

While "RPP0B Antibody" is unverified, research on antibody validation for RPPA workflows highlights critical quality-control steps:

Key Criteria for Antibody Reliability in RPPA:

• Specificity: Western blot validation for single-band detection (e.g., antibodies against CD20, PAX5, and C-MYC in DLBCL studies ).

• Reproducibility: Inter-laboratory consistency checks (e.g., AUC >0.8 in ROC analysis for CD5 and C-MYC ).

• Dynamic Range: Linear detection across protein concentrations (e.g., RPPA-adjusted CD20 normalization ).

Technical Limitations

The absence of "RPP0B" in existing datasets could indicate:

• Target Obscurity: A novel or poorly characterized antigen not yet widely studied.

• Commercial Availability: Lack of commercial development due to low demand or technical challenges.

Recommendations for Further Investigation

To resolve this discrepancy:

1. Verify the gene symbol or UniProt ID associated with "RPP0B" to confirm its existence.

2. Explore orthologous targets (e.g., ribosomal or RNA-processing proteins with similar naming conventions).

3. Consult antibody repositories like the Human Protein Atlas or CiteAb for unpublished datasets.